1099.HK
600511.SHG
111 does healthcare

Drug wholesaler and retailer Sinopharm Group Co. Ltd. (1099.HK; 600511.SH) on Wednesday reported its revenue increased 6.6% year-over-year to 13.56 billion yuan ($1.99 billion) in the first quarter, while its profit rose 3.3% to 474 million yuan. Its core profit, which excludes non-recurring gains and losses, rose 4.2% to 465 million yuan.

Despite growth in both revenue and profit, the company’s cash flow situation remained shaky. It generated nearly 3.6 billion yuan in net cash outflow from operating activities during the quarter, up nearly 90% from a 1.89 billion yuan outflow a year earlier.

Shares of Sinopharm opened flat at HK$19.83 on Thursday. The stock is down over 10% from its 52-week high.

By Lau Chi Hang             

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

TAL provides education services

Steep loss mars TAL Education’s comeback

A $47.4 million expense in its latest fiscal quarter may be linked to the educator’s 2025 acquisition of a bankrupt U.S. company Key Takeaways: TAL Education’s net revenues increased by…